Liu Xunqiang, Jia Zheng, Chen Huanjun, Yang Ying, Li Cuihong, Ji Min, Yang Chunxin, Zhang Jinhui, Cong Lei, Li Jiaqi, Wei Yan, Zhang Liqiong, Zhu Enshuai, Li Ruhong
Department of Vascular Intervention, Yan'an Hospital, Kunming Medical University, Kunming, China.
Department of Pharmacy, Yan'an Hospital, Kunming Medical University, Kunming, China.
Cardiovasc Intervent Radiol. 2025 Sep 11. doi: 10.1007/s00270-025-04122-7.
To assess the clinical benefits and complications of thoracic endovascular aneurysm repair (TEVAR) using a single-branched stent-graft in patients with thoracic aortic diseases (TADs) involving the left subclavian artery (LSA).
This retrospective study reviewed patients with TADs involving the LSA treated with TEVAR using a unibody single-branched stent-graft (Castor single-branched stent-graft, Shanghai MicroPort Endovascular (Group) MedTech Co., Ltd.) from November 2017 to May 2021. Clinical follow-ups and computed tomographic angiography (CTA) were conducted at 1 week, 3 months, 6 months, and annually.
A total of 114 patients underwent TEVAR with Castor stent-graft. Among 114 patients, 88 had TBAD, 14 had PAU, 6 had pseudoaneurysms, 3 had TAA, and 2 had IMH. Technical success (defined as successful deployment and patency of all stent segments) was 100%. No mortality, endoleak, stroke, or paraplegia was observed during a mean follow-up of 19.8 months. One case of LSA occlusion (0.9%) was noted at 3-month follow-up, without neurological symptoms.
The Castor single-branched stent-graft is effective for treating TADs involving the LSA, with high technical success and no short- or midterm complications. Further research is needed to confirm long-term safety and efficacy.
评估使用单分支覆膜支架对累及左锁骨下动脉（LSA）的胸主动脉疾病（TADs）患者进行胸主动脉腔内修复术（TEVAR）的临床益处和并发症。
这项回顾性研究纳入了2017年11月至2021年5月期间使用一体式单分支覆膜支架（Castor单分支覆膜支架，上海微创心脉医疗科技（集团）股份有限公司）接受TEVAR治疗的累及LSA的TADs患者。在术后1周、3个月、6个月及每年进行临床随访和计算机断层血管造影（CTA）检查。
共有114例患者接受了Castor支架型人工血管TEVAR治疗。114例患者中，88例患有胸主动脉夹层（TBAD），14例患有穿透性主动脉溃疡（PAU），6例患有假性动脉瘤，3例患有胸主动脉瘤（TAA），2例患有主动脉壁内血肿（IMH）。技术成功率（定义为所有支架段成功植入且通畅）为100%。在平均19.8个月的随访期内，未观察到死亡、内漏、中风或截瘫病例。3个月随访时发现1例LSA闭塞（0.9%），无神经症状。
Castor单分支覆膜支架治疗累及LSA的TADs有效，技术成功率高，无短期或中期并发症。需要进一步研究以证实其长期安全性和有效性。
